Glioblastoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Glioblastoma-related gene mutations and over-expression of functional epidermal growth factor receptors in SKMG-3 glioma cells.
|
11515790 |
2001 |
Glioblastoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
EGF receptor variant III (EGFRvIII) is the most common variant of the EGF receptor and has been detected in a large percentage of patients with glioblastoma multiforme but not in normal brain.
|
20404701 |
2010 |
Glioblastoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Epidermal growth factor module-containing mucin-like receptor 2 is a newly identified adhesion G protein-coupled receptor associated with poor overall survival and an invasive phenotype in glioblastoma.
|
21503828 |
2011 |
Glioblastoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Epidermal growth factor receptors (EGFR) expression is frequently amplified in human glioblastoma cells.
|
24012640 |
2014 |
Glioblastoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Epidermal growth factor (EGF)-enhanced vascular cell adhesion molecule-1 (VCAM-1) expression promotes macrophage and glioblastoma cell interaction and tumor cell invasion.
|
24045955 |
2013 |
Glioblastoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
A glioblastoma stem cell (GSC) line, GSC11, grows as neurospheres in serum-free media supplemented with EGF (epidermal growth factor) and bFGF (basic fibroblast growth factor), and, if implanted in nude mice brains, will recapitulate high-grade glial tumors.
|
20199106 |
2010 |
Glioblastoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
A bispecific ligand-directed toxin (BLT), called EGFATFKDEL, consisting of human epidermal growth factor, a fragment of urokinase, and truncated pseudomonas exotoxin (PE38) was assembled in order to target human glioblastoma.
|
20830604 |
2011 |
Glioblastoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
A mechanism for the upregulation of EGF receptor levels in glioblastomas.
|
23770238 |
2013 |
Glioblastoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
A mutant epidermal growth factor (EGF) receptor missing 267 amino acids from the exoplasmic domain is common in human glioblastomas.
|
11087732 |
2001 |
Glioblastoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Abnormal activation of epidermal growth factor receptors (EGFRs) due to amplification, mutation, or both of the <i>EGFR</i> gene is common in glioblastomas.
|
31284441 |
2019 |
Glioblastoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
According to the prevailing model, NHE9 overexpression leads to an increase in plasma membrane density of epidermal growth factor receptors (EGFRs) which consequently enhances GBM cell proliferation and migration.
|
31532058 |
2019 |
Glioblastoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Activation of the Elk-1 led to an increased survival and a proliferative response with the EGF stimulation in the U138 glioblastoma cells.
|
22085529 |
2012 |
Glioblastoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Altered expression of the suppressors PML and p53 in glioblastoma cells with the antisense-EGF-receptor.
|
10576656 |
1999 |
Glioblastoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Amplification of the EGFR gene can be maintained and modulated by variation of EGF concentrations in in vitro models of glioblastoma multiforme.
|
28934307 |
2017 |
Glioblastoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Anti-synthetic peptide antibody reacting at the fusion junction of deletion-mutant epidermal growth factor receptors in human glioblastoma.
|
1693434 |
1990 |
Glioblastoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Because oncogene MET and EGF receptor (EGFR) inhibitors are in clinical development against several types of cancer, including glioblastoma, it is important to identify predictive markers that indicate patient subgroups suitable for such therapies.
|
22203985 |
2012 |
Glioblastoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Compensatory activation of related ERBB family receptors (ERBB2 and ERBB3) was observed in GBM CSCs deprived of EGFR signal (EGF deprivation or cetuximab inhibition), suggesting an intrinsic GBM resistance mechanism for EGFR-targeted therapy.
|
22745588 |
2012 |
Glioblastoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Connecting signaling and metabolic pathways in EGF receptor-mediated oncogenesis of glioblastoma.
|
31386654 |
2019 |
Glioblastoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Crosstalk between the urokinase-type plasminogen activator receptor and EGF receptor variant III supports survival and growth of glioblastoma cells.
|
21896743 |
2011 |
Glioblastoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
DAB(389)EGF may have potential for intracranial therapy of EGFR-positive glioblastomas.
|
12702570 |
2003 |
Glioblastoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Diphtheria toxin-epidermal growth factor fusion protein and Pseudomonas exotoxin-interleukin 13 fusion protein exert synergistic toxicity against human glioblastoma multiforme cells.
|
14624623 |
2004 |
Glioblastoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Direct mTOR inhibitors and EGF receptor (EGFR) inhibitors that block downstream mTOR signaling promote nuclear PML expression in GBMs, and genetic overexpression and knockdown approaches demonstrate that PML prevents mTOR and EGFR inhibitor-dependent cell death.
|
23440206 |
2013 |
Glioblastoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Finally, glioblastomas may emerge from the microenvironmental outgrowth of more malignant clones in a complex vicious cycle that involves necrosis, hypoxia, growth factor release, angiogenesis and clonal selection; growth signals mediated by activation of epidermal growth factor receptors may precipitate glioblastomas.
|
9161727 |
1997 |
Glioblastoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Growth suppression of intracranial xenografted glioblastomas overexpressing mutant epidermal growth factor receptors by systemic administration of monoclonal antibody (mAb) 806, a novel monoclonal antibody directed to the receptor.
|
11454673 |
2001 |
Glioblastoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Hemizygous or homozygous deletion of the chromosomal region containing the p16INK4a gene is associated with amplification of the EGF receptor gene in glioblastomas.
|
9334810 |
1997 |